prima gains partner, grant eligibility

some press exposure on the very impressive German deal:

article 1.Prima gains partner, grant eligibility

Thursday, 27 May 2010
OVARIAN cancer immunotherapy developer Prima BioMed has entered into a partnership with Germanys Fraunhofer Institute for Cell Therapy which will see the partner produce CVac cancer immunotherapy product for European clinical trials.
Through the agreement, Prima will be eligible for substantial research and development grants from Germanys Free State of Saxony.

This will subsidise a significant part of CVacs European production costs, the company said yesterday.

Prima BioMed chief executive Martin Rogers said the company was delighted to bring Fraunhofer on board to the CVac program.

The European trial is a Phase 3 and will kick off later this year.

A Phase 2b trial is underway in the United States, under the auspices of the US Food and Drug Administration.

In a statement, Prima chief operating officer and managing director for Europe, Matthew Lehman said Fraunhofer was among the foremost research and development organisations in the world.

http://www.biotechnologynews.net/storyview.asp?storyid=1136142§ionsource=s0



article 2.

Prima BioMed forms European trial partnership
Business Spectator: May 27, 2010

http://www.businessspectator.com.au/bs.nsf/Article/Prima-BioMed-forms-European-trial-partnership-

Prima BioMed Ltd has entered into an agreement with the Fraunhofer Institute for Cell Therapy and Immunology (Fraunhofer IZI) in Leipzig, Germany to produce Primas CVac cancer immunotherapy product for European clinical trials in early 2011.
The agreement also allows Prima to be eligible for millions of euros in R&D grants from the Saxony Bank. These grants are intended to assist small companies in product development to achieve success, and would subsidise a significant part of Primas production cost for CVac. The agreement with Fraunhofer also provides other key benefits to Prima through its collaborative networks throughout academia, government, and industry. Fraunhofer will help enhance the visibility of the CVac clinical program in Europe and globally.


article 3.

Brief: Prima BioMed
Australian Financial Review 27 May 2010

http://afr.com/p/business/companies/brief_prima_biomed_fdnXkghMvNkeODw1RTGVoL

Prima BioMed has an agreement with the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig, Germany, to produce Primas CVac cancer immunotherapy product for the European clinical trials.